On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is a large bet, aimed at a wave of biologic patent expirations that Amneal estimates could open up more than $300 billion in sales over the next ten years.
A Decade-Long Growth Bet
Amneal and Kashiv have worked together for more than ten years, which gives the combined business a head start most acquisitions do not get. Management expects the merged platform to support a steady stream of biosimilar launches, stretching Amneal’s runway for growth well past 2030 and into territory few generic drugmakers can plan for today.
That ambition rests on a business that was already gaining speed before the deal closed. Second quarter 2026 net revenue came in at $796 million, up 10% from $725 million a year earlier, with Specialty products like CREXONT and the BREKIYA autoinjector pushing that segment’s revenue up 17%. Net income more than doubled to $58 million from $22 million, and adjusted EBITDA climbed 12% to $206 million.
Those results were strong enough that Amneal lifted its full-year revenue outlook to a range of $3.10 billion to $3.20 billion, its second upward revision of 2026. A July repricing of its $2.084 billion term loan is also expected to trim about $12 million a year in interest expense, part of a broader push to bring net leverage under 3.0 times by 2028.
The Price Of Ambition
None of this comes free. To help cover the Kashiv purchase price, Amneal is layering on an additional $350 million term loan even as it works to reprice its existing debt lower. Full-year capital expenditure guidance was also bumped up, from roughly $110 million to about $150 million, a sign that absorbing Kashiv’s manufacturing and development operations will cost more than a simple bolt-on deal. Amneal’s own cash flow guidance sets aside around $30 million in Kashiv acquisition and integration costs and $36 million tied to opioid settlements, both real cash outlays sitting just outside the headline figures.
Not every part of Amneal’s business is contributing, either. AvKARE, its government distribution unit, saw revenue slide 4% in the second quarter, which the company pinned on a weaker low-margin distribution channel. And while Amneal says integration planning is already in motion, the deal only closed on August 10, 2026, so the real work of merging Kashiv’s labs and plants into Amneal’s operations still lies ahead.
What The Numbers Show
Hedge fund ownership of Amneal slipped from 36 funds to 23 in the most recent quarter, a notable pullback in institutional interest. Short sellers have not followed suit, though, with just 3.88% of the float sold short, a level that points to little organized skepticism. That is an unusual pairing: fewer funds in the stock, but no rush to bet against it either. The result is a market that seems undecided rather than convinced in either direction.
What Comes Next
Amneal spent 2026 raising its guidance and lowering its borrowing costs while also taking on new debt to fund its largest strategic move in years. The Kashiv deal gives the company a genuine shot at building a lasting biosimilars business ahead of a historic round of biologic patent expirations. But integration has barely begun, spending is rising, and one part of the portfolio is already shrinking. Whether the growth case wins out will depend on how quickly the combined platform starts delivering the launches management has promised.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Follow Insider Monkey on Google News.
